PNT - POINT Biopharma adds nearly 10% most in three months after naming COO

POINT Biopharma (PNT +9.9%) has recorded the biggest intraday gain since early September after the company announced several changes to its senior leadership team. Justyna Kelly, Vice President, Medical Isotope Development and Operations has been promoted to the role of Chief Operating Officer, effective Dec. 01. An 11-year veteran in the field of radiopharmaceuticals, Kelly has expertise in sterility assurance programs, GMP manufacturing sites, and in the management of development programs. The company has also promoted Robin Hallett, Senior Director, Preclinical Development as Vice President, Discovery and Translational Sciences with effect from Dec. 01. Meanwhile, Sherin Al-Safadi, — a former Global Medical Affairs Oncology Strategy director at Bayer — is expected to take over the role of Vice President, Medical Affairs effective Dec. 13.

For further details see:

POINT Biopharma adds nearly 10% most in three months after naming COO